GlassBury AI combines agentic patient matching with culturally sensitive community education to eliminate healthcare disparities. By pairing AI with expert-curated workshops, we build the trust necessary to connect underrepresented patients with life-changing clinical trials.
The Future of Drug Research Privacy: Navigating Evolving Regulations
Drug research is a critical endeavor that pushes the boundaries of medical science, leading to the development of life-saving treatments and therapies. However, this vital process involves collecting and analyzing sensitive personal data from research participants, raising important ethical and privacy concerns. As technology advances and data collection methods become more sophisticated, the need for robust privacy regulations in drug research is more pressing than ever.
The Regulatory Shift: From Optional Inclusion to Mandatory Action
Learn how Glassbury AI bridges grassroots engagement and LLM companions to meet FDA Diversity Action Plan compliance and solve Alzheimer's trial enrollment.
The Hurdles in the Path to Cures: The Unique Challenges of Rare Disease Research
Rare diseases, despite affecting millions of people worldwide, often exist in a shadow cast by more prevalent illnesses. Their rarity presents a unique set of challenges for researchers striving to develop effective treatments and cures. From limited funding to small patient populations, the path to conquering rare diseases is fraught with obstacles.
The Ripple Effect of Altruism: Why Unconditional Love Matters
In today's fast-paced, self-centered world, it's easy to get caught up in the pursuit of personal gain and happiness. We are constantly bombarded with messages promoting individual success and the accumulation of wealth and possessions. However, amidst this relentless focus on self, there's a growing recognition of the transformative power of altruism – the selfless act of caring for others without expecting anything in return. In this blog post, we will explore the profound impact of altruistic love and why it is essential for building a more compassionate and fulfilling world.
Finding Inner Peace: Contemplative Meditation for Alzheimer's Caregivers
Caring for a loved one with Alzheimer's disease can be an emotionally and physically exhausting journey. The constant demands, coupled with the heartbreak of witnessing the gradual decline of a once-familiar person, can take a significant toll on caregivers' well-being.
The Role of Government in Fostering a Thriving Entrepreneurial Environment for Drug Research and Development
The United States government plays a pivotal role in shaping the landscape for drug research and development (R&D), fostering an environment where entrepreneurial endeavors can flourish. This blog post delves into the multifaceted ways in which the government contributes to this ecosystem, drawing insights from authoritative sources and expert opinions.
Caregivers and Mental Health: The Unsung Heroes Need Support Too
Caregiving is an act of profound love and dedication, but it can also be a challenging journey filled with emotional, physical, and mental strain.
Combating Alzheimer's: Current Treatments and Promising Pipeline Drugs
Alzheimer's disease is a devastating neurodegenerative disorder that affects millions worldwide. As the global population ages, the prevalence of Alzheimer's and related dementias is expected to rise significantly.
A Son's Reflections on Caring for His Dying Mother by Corey Hubbard
When I first became a caregiver for my terminally ill mother, I was thrust into a world I was wholly unprepared for. The woman who had always been my pillar of strength, my source of unwavering support, was now vulnerable and dependent on me.
Eliminating Bias in Pre-Screening: How Agentic AI Parses Unstructured EHR Notes for Alzheimer’s Research
Discover how Glassbury AI’s agentic architecture and zero-text FHIR mapping help biopharma sponsors achieve FDA Diversity Action Plan (DAP) compliance and eliminate Alzheimer’s trial screen failures.
The Regulatory Shift: Why Diversity Is Now a Technical Requirement
Discover how Glassbury AI’s agentic NLP platform, SYCQ 1.0, solves the FDA Diversity Action Plan (DAP) mandate and accelerates Phase III Alzheimer’s clinical trial matching.
AI Meets the Genome: The September 2026 Breakthroughs Decoding Alzheimer’s
Discover how AI models analyzing structural 3D genome folding and speech biometrics published in mid-September 2026 are cracking Alzheimer's mysteries.
Beyond Plaques & Tangles: The Brand-New Genomic & Micro-Wiring Discoveries Reshaping Alzheimer’s
Explore brand-new September 2026 breakthroughs in Alzheimer's research, from Salk's hidden microproteins to 3D genome folding and protective brain wiring.
Beyond Clearing Trash: Blocking the IDOL Enzyme Could Revolutionize Alzheimer's Care
Indiana University researchers have discovered that blocking the IDOL enzyme in neurons doesn't just clear toxic Alzheimer's plaques—it also lowers genetic risk (APOE4) and builds cognitive resilience. Read on to learn how this discovery could pave the way for a revolutionary new pill.
FDA Clears Elecsys pTau217 Blood Test: A Game-Changer for Alzheimer's Diagnosis
The FDA has cleared the Elecsys pTau217 blood test for Alzheimer's. Discover how this single-biomarker assay boosts primary care diagnostic accuracy from 65% to 93%.
The Dawn of a New Era in Alzheimer’s Care: From Simple Blood Tests to At-Home Treatments
Discover how the new p-tau217 blood test and the LEQEMBI IQLIK® autoinjector are revolutionizing Alzheimer's diagnosis and treatment at home.
The Real Cost of Memory Loss: Caregivers and Clinical Trial Diversity Matter
Learn about the true economic and social impact of Alzheimer's, the burden on unpaid caregivers, and why diversity in medical research is key to a cure.
Alzheimer’s Breakthrough: Why Tau-Targeting Therapies Are Changing the Game
Explore how tau-targeting drug Diranersen and a newly diversified research pipeline are reshaping Alzheimer's treatment and slowing cognitive decline.
Alzheimer’s Breakthroughs: Atypical Variants and New Pathways
Discover how modern neurology is moving beyond amyloid to tackle atypical Alzheimer’s variants, neuroinflammation, and systemic factors for personalized care.
Why Anti-Amyloid Alzheimer's Treatments Need a Lifestyle Boost
Discover why new Alzheimer's antibody treatments like lecanemab aren't enough on their own and why daily habits like exercise and diet play a critical role in brain health.